Pexidartinib is a systemic treatment for patients with tenosynovial giant cell tumor not amenable to surgery.
Development of a physiologically based pharmacokinetic model for levetiracetam in patients with renal impairment to guide dose adjustment based on steady-state peak/trough concentrations
Levetiracetam may cause acute renal failure and myoclonic encephalopathy at high plasma levels, particularly in patients with renal impairment.
Predicting Human Dermal Drug Concentrations Using PBPK Modeling and Simulation: Clobetasol Propionate Case Study
Quantitative in silico tools may be leveraged to mechanistically predict the dermato-pharmacokinetics of compounds delivered from topical and transdermal formulations by integrating systems of rate equations...
Accelerated and Biopredictive In Vitro Release Testing Strategy for Single Agent and Combination Long-Acting Injectables
The purpose of this study was to develop an in vitro release testing (IVRT) strategy to predict the pre-clinical performance of single agent and combination long acting injectable (LAI) suspension products.
Simulations Plus Extends Collaboration with Major Toxicology Research Agency
Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use.
Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
This study was designed to verify a virtual population representing patients with nonalcoholic fatty liver disease (NAFLD) to support the implementation of a physiologically based pharmacokinetic (PBPK) modeling...
The AI‑driven Drug Design (AIDD) platform: an interactive multi‑parameter optimization system integrating molecular evolution with physiologically based pharmacokinetic simulations
Computer-aided drug design has advanced rapidly in recent years, and multiple instances of in silico designed molecules advancing to the clinic have demonstrated the contribution of this field to medicine.
Simulations Plus Launches Corporate Development Initiative
Strategic investments in early-stage companies to drive innovation and collaboration
February 2024 GastroPlus Newsletter
GastroPlus® Newsletter February 2024
Human biomonitoring and toxicokinetics as key building blocks for next generation risk assessment
Human health risk assessment is historically built upon animal testing, often following Organisation for Economic Co-operation and Development (OECD) test guidelines and exposure assessments.
Development of an extemporaneous preparation formulation using a simple and non-solubilizing matrix for first in human clinical study
Extemporaneous preparation (EP) formulation is an attractive strategy to accelerate the formulation development of new chemical entities for first entry into human study.
Integrating Artificial Intelligence for Drug Discovery in the Context of Revolutionizing Drug Delivery
Drug development is expensive, time-consuming, and has a high failure rate.
February 2024 News/Events
Unlocking the Power of PBPK Modeling
Simulations Plus to Participate in Upcoming Healthcare Conferences
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.
Accurate Prediction of Kp,uu,brain Based on Experimental Measurement of Kp,brain and Computed Physicochemical Properties of Candidate Compounds in CNS Drug Discovery
A mathematical equation model was developed by building the relationship between the fu,b/fu,p ratio and the computed physicochemical properties of candidate compounds, thereby predicting Kp,uu,brain based on a single experimentally measured Kp,brain value.
Simulations Plus Releases GastroPlus® Version 9.9
New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models
Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models
Physiologically based pharmacokinetic (PBPK) modeling is a paradigm shift in this era for determining the exposure of drugs in pediatrics, geriatrics, and patients with chronic diseases where clinical trials are difficult to conduct.
Application of a new MDCKII-MDR1 cell model to measure the extent of drug distribution in vitro at equilibrium for prediction of in vivo unbound brain-to-plasma drug distribution
Reliable estimates of drug uptake from blood to brain parenchyma are crucial in CNS drug discovery and development.
Using QST Predictions to Optimize Your Drug, De-Risk Your Regulatory Submission, and Guide R&D
After investing years into developing and optimizing a new drug, it’s some of the worst news you can hear: your clinical trials are showing potential liver toxicity.